Abstract
In recent decades we have seen an exponential interest in the implications of integrin receptors in cancer biology and especially in prostate tumour development. Integrins has been reported to control multiple mechanisms, such as cell survival, proliferation, differentiation, and migration. Here, we report the current understanding of the integrin signalling mechanisms in metastatic prostate tumour development, cross-talks between the primary and metastatic sites on tumour growth, interactions between tumour cells and tissue microenvironment, and epithelial-mesenchymal transition (EMT). Finally, this review presents the integrin-based chemotherapeutic agents currently under clinically consideration and provides an insight into cancer drug development using integrin as a target.
Keywords: Antagonist therapy, integrin, prostate cancer.
Current Drug Targets
Title:Therapeutic Value of an Integrin Antagonist in Prostate Cancer
Volume: 17 Issue: 3
Author(s): Clément-Lacroix Philippe
Affiliation:
Keywords: Antagonist therapy, integrin, prostate cancer.
Abstract: In recent decades we have seen an exponential interest in the implications of integrin receptors in cancer biology and especially in prostate tumour development. Integrins has been reported to control multiple mechanisms, such as cell survival, proliferation, differentiation, and migration. Here, we report the current understanding of the integrin signalling mechanisms in metastatic prostate tumour development, cross-talks between the primary and metastatic sites on tumour growth, interactions between tumour cells and tissue microenvironment, and epithelial-mesenchymal transition (EMT). Finally, this review presents the integrin-based chemotherapeutic agents currently under clinically consideration and provides an insight into cancer drug development using integrin as a target.
Export Options
About this article
Cite this article as:
Philippe Clément-Lacroix, Therapeutic Value of an Integrin Antagonist in Prostate Cancer, Current Drug Targets 2016; 17 (3) . https://dx.doi.org/10.2174/1389450117666151209115324
DOI https://dx.doi.org/10.2174/1389450117666151209115324 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Engineered Inorganic/Organic-Core/Shell Magnetic Fe<sub>x</sub>O<sub>y</sub> Nanoparticles with Oleic Acid and/or Oleylamine As Capping Agents
Current Pharmaceutical Design Specific Direct Small Molecule p300/β-Catenin Antagonists Maintain Stem Cell Potency
Current Molecular Pharmacology AGE-RAGE System and Carcinogenesis
Current Pharmaceutical Design miRNAs in Gastrointestinal and Liver Cancers: Their Perspectives and Clinical Applications
Current Pharmaceutical Design Stem Cell Differentiation Stage Factors and their Role in Triggering Symmetry Breaking Processes during Cancer Development: A Quantum Field Theory Model for Reprogramming Cancer Cells to Healthy Phenotypes
Current Medicinal Chemistry Glycosylated Antitumor Ether Lipids: Activity and Mechanism of Action
Anti-Cancer Agents in Medicinal Chemistry Strategies for Effective Naked-DNA Vaccination Against Infectious Diseases
Recent Patents on Anti-Infective Drug Discovery How is Gene Transfection Able to Improve Current Chemotherapy? The Role of Combined Therapy in Cancer Treatment
Current Medicinal Chemistry Synthesis, Molecular Docking and Pharmacological Study of Pyrimidothiadiazinones and its bis-derivatives
Letters in Drug Design & Discovery Identification of KEY lncRNAs and mRNAs Associated with Oral Squamous Cell Carcinoma Progression
Current Bioinformatics Antioxidant, Anti-Inflammatory and Anticancer Activities of the Methanolic Extract of Thottea siliquosa: An <i>In Vitro</i> and <i>In Silico</i> Study
Recent Patents on Anti-Cancer Drug Discovery Systematic Evaluation of the Mechanisms of Mulberry Leaf (Morus alba Linne) Acting on Diabetes Based on Network Pharmacology and Molecular Docking
Combinatorial Chemistry & High Throughput Screening Formation of Nanostructures by Peptides
Current Protein & Peptide Science Promising Gene Therapy Using an Adenovirus Vector Carrying REIC/Dkk-3 Gene for the Treatment of Biliary Cancer
Current Gene Therapy Cell Penetrating Peptides for In Vivo Molecular Imaging Applications
Current Pharmaceutical Design NF-κB Down–regulation and PARP Cleavage by novel 3-α-butyryloxy-β-boswellic Acid Results in Cancer Cell Specific Apoptosis and in vivo Tumor Regression
Anti-Cancer Agents in Medicinal Chemistry Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology The Posttranslational Phase of Gene Expression: New Possibilities in Molecular Diagnosis
Current Molecular Medicine Membrane Tyrosine Kinase Receptors Kit and FLT3 are an Important Targets for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets